Get the Stockscreener App
238.68
0.97%
-2.34
Bio Rad Laboratories Inc stock is traded at $238.68, with a volume of 244.72K.
It is down -0.97% in the last 24 hours and down -4.21% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$241.02
Open:
$240.94
24h Volume:
244.72K
Relative Volume:
0.68
Market Cap:
$6.43B
Revenue:
$2.58B
Net Income/Loss:
$-778.69M
P/E Ratio:
-8.7333
EPS:
-27.33
Net Cash Flow:
$223.75M
1W Performance:
+0.99%
1M Performance:
-4.21%
6M Performance:
-35.36%
1Y Performance:
-13.93%
1-Day Range:
$238.09
$243.15
1-Week Range:
$228.91
$243.75
52-Week Range:
$215.38
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
238.68 | 6.43B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Elisa Analyzer Market Grows Due to Demand for Quick and Accurate - openPR.com
Bio-Rad: With Low Debt And A Stock Price Drop, Is The Company Undervalued? (NYSE:BIO) - Seeking Alpha
Proteomics Market to Reach $161.9 billion, Globally, by 2035 - openPR.com
Cell-Based Assay Market Top Players- Becton, Dickinson - openPR.com
How To Trade (BIO.B) - news.stocktradersdaily.com
Paper Diagnostics Market Set to Witness Significant Growth by 2025-2032 | Abbott (Alere Inc.), Bio-Rad Laboratories - openPR.com
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR - GlobeNewswire Inc.
Sample Preparation Market Grows with Automation and Diagnostic - openPR.com
Antimicrobial Susceptibility Testing Market Report Insights, - openPR.com
Molecular Diagnostics Market Sees Strong Growth Driven by Rise - openPR.com
Custom Antibody Market To Hit USD 1,230.09 Billion By 2032 | - openPR.com
Polymerase Chain Reaction Market Set to Witness Significant - openPR.com
Enzyme Linked Immunosorbent Assay Market Deep Research - openPR.com
Bio-Rad Reports First-Quarter 2025 Financial Results - ADVFN
Fund Update: First Pacific Advisors, LP added 214,705 shares of BIO-RAD LABORATORIES ($BIO) to their portfolio - Nasdaq
U.S. Hemoglobinopathy Market 2025-2032: Top Trends & Growth - openPR.com
One Step RT-qPCR Kits Market Top Players- Takara Bio Inc., - openPR.com
Laboratory Proficiency Testing Market Is Booming Worldwide | - openPR.com
Biodetection Market Deep Research 2025-2032 | Bio-Rad - openPR.com
Analysts Have Been Trimming Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target After Its Latest Report - Yahoo Finance
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Labora - GuruFocus
Bio-Rad Earnings: Revenue Declines Driven by Weak Academic Research Market; Guidance Lowered - Morningstar
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2024 Earnings Call Transcript - MSN
BIO: UBS Lowers Price Target But Maintains Buy Rating for Bio-Ra - GuruFocus
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions - MSN
BIO: UBS Lowers Price Target But Maintains Buy Rating for Bio-Rad Laboratories | BIO Stock News - GuruFocus
Bio-Rad Laboratories (BIO) Price Target Revised by Citigroup | B - GuruFocus
Bio-Rad Laboratories (BIO) Price Target Revised by Citigroup | BIO Stock News - GuruFocus
Bio-Rad's Steady Business and Stake in Sartorius Driving Long-Term Value - Morningstar
RBC Capital Lowers Price Target for Bio-Rad Laboratories (BIO) | - GuruFocus
RBC Capital Lowers Price Target for Bio-Rad Laboratories (BIO) | BIO Stock News - GuruFocus
Bio-Rad (BIO) Target Price Cut by UBS Amid Macroeconomic Concerns | BIO Stock News - GuruFocus
Bio-Rad (BIO) Sees Price Target Reduced by Citi Analyst After Q1 Report | BIO Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Biosensors Market Future Business Opportunities 2025-2032 | - openPR.com
UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating - marketscreener.com
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket - Yahoo Finance
Biomarker Testing Market: Trends, Growth, and Key Insights 2025 - openPR.com
Bio-Rad Laboratories Q1 Adjusted Earnings Rise, Revenue Falls - marketscreener.com
Bio-Rad Laboratories Inc (BIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo
The Best Healthcare Stocks to Buy - Morningstar
Bio Rad Laboratories Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bio-Rad: Q1 Earnings Snapshot - MySA
Bio-Rad Laboratories Reports Q1 2025 Financial Results - TipRanks
Bio-Rad Laboratories (BIO) Faces Revenue Challenges Amid Market Headwinds - GuruFocus
Bio-Rad Laboratories Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Bio-Rad Labs exceeds Q1 2025 earnings expectations - Investing.com
Bio-Rad Labs beats Q1 estimates, lowers 2025 outlook By Investing.com - Investing.com South Africa
Bio-Rad Labs beats Q1 estimates, lowers 2025 outlook - Investing.com
Bio-Rad Laboratories Expects 2025 Non-GAAP Revenue to Range From 1% Drop to 1.5% Growth Vs. Prior Est 1.5% to 3.5% Gain - marketscreener.com
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):